Twenty-five new therapies, ten oncological and fifteen non-oncological, will bring patients the July reimbursement list. As Deputy Health Minister Katarzyna Kacperczyk said on Thursday, the announcement will be signed on Wednesday, there may still be some change on it.
What's new on the reimbursement list (and more)?
Published June 12, 2026 10:29
Fot. Jacek Sielski
The ministry also announced that 156 decisions have been made to continue reimbursing drugs that are already in the system.
The July list will include new therapies for lung cancer. With good reason: epidemiological data show that the incidence of these cancers is increasing, including among women and young people, which the ministry links to the high popularity of new tobacco products: the popularity of traditional cigarettes is declining, while the popularity of e-cigarettes and other novel devices is growing and growing at a dizzying pace. Katarzyna Kacperczyk appealed not to reach for such alternative methods of smoking. At the same time, the Ministry of Health decided to extend reimbursement to nivolumab and durvalumab, among others. As the deputy minister stressed, the decision reflects a strategic change in the philosophy of cancer treatment, as the MZ is betting on introducing advanced therapies at an early stage of the disease, and not only when metastases appear. With this approach, it will be possible to cure patients completely.
As for non-oncology therapies, the list includes drugs for population diseases as well as rare or ultra-rare diseases.
The Ministry has also presented a new list of therapies with well-established efficacy (this time in the areas of endocrinology, urology and gynecology, among others) - quick reimbursement decisions are possible, without having to go through the whole process, "just" reaching a price agreement. Patients with urinary incontinence, among others, will be waiting for a positive outcome, as one of the drugs addresses this very disease.
There is also a list of innovative therapies (the Ministry of Health has selected seven out of nine proposals), which will also be able to count on financing in a simplified procedure, provided agreement is reached on the price. - We have PLN 1.1 billion every year for innovative technologies, which are selected from a list of new drugs approved by the European Medicines Agency (EMA) and accepted after consultations by the Minister of Health, Kacperczyk said. The proposal for the list is prepared by AOTMiT, and then consulted with the Patient Ombudsman and the Transparency Council.
The list includes givinostat, used to treat Duchenne muscular dystrophy, and sepiapterin, used to treat phenylketonuria, and vorasideneib (a treatment for glioblastoma).
